Nor and Nord's pre-market drop by nearly 4%, as the clinical trial data for their new weight-loss drug is below expectations.

Novo Nordisk pre-market fell nearly 4% to $70.87. In terms of news, Novo Nordisk disclosed the complete data from its Phase III clinical trials of the new weight-loss drug CagriSema, showing positive results in weight loss and metabolic improvements, but with a higher rate of gastrointestinal side effects compared to the placebo group. This result is basically consistent with previously released interim data, but did not fully meet the expectations of the capital market. Novo Nordisk had previously announced details of a 68-week clinical study at the American Diabetes Association annual meeting in Chicago, showing an average weight loss of about 23% in overweight or obese non-diabetic patients receiving CagriSema treatment, and a weight loss of 15.8% in overweight patients with type 2 diabetes.